Home blood count monitoring and self-administered transfusions for adults with AML
Feasibility and Safety of Home Blood Count Measurement and Transfusions by Systematically Educated Patients With Acute Myeloid Leukemia
This project will test whether adults newly diagnosed with AML can safely measure their own blood counts at home and self-administer blood and platelet transfusions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rigshospitalet, Denmark Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT07062250 on ClinicalTrials.gov |
What this trial studies
This single-arm feasibility study at Rigshospitalet will train adults newly diagnosed with AML to perform point-of-care complete blood count measurements and to self-administer prescribed blood and platelet transfusions at home. Participants will record vital signs (blood pressure, pulse, oxygen saturation, temperature) before and after each transfusion while clinicians monitor for complications and transfusion reactions. The protocol collects safety data, adherence metrics, patient-reported experiences, and health-economic outcomes related to reduced nurse-driven services and hospital visits. Patients who do not achieve remission after the second chemotherapy cycle will be discontinued from the intervention.
Who should consider this trial
Good fit: Adults (≥18) newly diagnosed with AML within four weeks who are scheduled for home-based chemotherapy, speak Danish, and are judged capable of performing home blood measurements and self-transfusions are ideal candidates.
Not a fit: Patients who do not speak Danish, who lack the physical or cognitive ability to perform home monitoring or self-transfusions, or who fail to achieve remission after the second chemotherapy cycle are unlikely to benefit.
Why it matters
Potential benefit: If successful, the approach could reduce hospital visits and nurse workload while allowing patients to spend more time at home during periods of low blood counts.
How similar studies have performed: Home transfusions administered by healthcare professionals or relatives have been shown to be feasible and generally safe in prior work, but fully self-administered transfusions have not been studied and remain largely untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years old * newly diagnosed with AML within four weeks * scheduled to receive home-based chemotherapy. Exclusion Criteria: * Patients who do not understand or speak Danish * Incapable of performing home-based CBC measurements and administration of transfusions. * Patients will be discontinued if they do not achieve remission after the second chemotherapy cycle.
Where this trial is running
Copenhagen
- Rigshospitalet — Copenhagen, Denmark (Recruiting)
Study contacts
- Principal investigator: Lars Kjeldsen, MD — Rigshospitalet, Denmark
- Study coordinator: Iben H Nielsen, PhD
- Email: iben.husted.nielsen@regionh.dk
- Phone: +4526227757
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.